阳光诺和收盘上涨4.22%，滚动市盈率28.56倍，总市值50.67亿元

Company Overview - Beijing Sunshine Nuohe Pharmaceutical Research Co., Ltd. specializes in comprehensive preclinical and clinical drug research services, providing a one-stop drug development service for domestic pharmaceutical companies and research institutions [2] - The company aims to assist domestic pharmaceutical manufacturers in accelerating import substitution and independent innovation [2] - Major products include drug discovery, pharmacology, pharmaceutical research, clinical research, and bioanalysis [2] Financial Performance - For the fiscal year 2024, the company reported a revenue of 1.078 billion yuan, representing a year-on-year increase of 15.70% [2] - The net profit for the same period was 177 million yuan, showing a year-on-year decrease of 3.98% [2] - The sales gross margin stood at 50.18% [2] Market Position - As of April 18, the company's stock closed at 45.24 yuan, with a PE ratio of 28.56, marking an 11-day low [1] - The total market capitalization is 5.067 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical services sector is 45.89, with a median of 48.60, placing Sunshine Nuohe at the 21st position in the industry ranking [1][3] Shareholder Information - As of March 31, 2025, the number of shareholders for Sunshine Nuohe reached 8,025, an increase of 455 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]